Nitric Oxide Tames Aggressive Prostate Cancer by Silencing a Key Stress Driver

Neuroendocrine prostate cancer (NEPC) emerges most often as an adaptive escape from androgen-deprivation therapy and accounts for up to 25% of prostate cancer deaths. It is defined by lineage plasticity—the ability of adenocarcinoma cells to transdifferentiate into an androgen-receptor-independent neuroendocrine phenotype—and by extreme therapy resistance. Current chemotherapy regimens offer only modest benefit, creating urgent demand for novel mechanistic targets.

This study centers on two intersecting biology problems: chronic endoplasmic reticulum (ER) stress driven by the oncogene MYCN, and dysregulated nitric oxide (NO) signaling. MYCN overexpression is a hallmark of NEPC; it reprograms gene expression, amplifies the unfolded protein response (UPR), and promotes calcium efflux from the ER into mitochondria, triggering glycolytic and oxidative stress that paradoxically feeds cancer cell survival. The researchers hypothesized that impaired endothelial NOS (eNOS/NOS3) activity in high-grade prostate cancer prevents S-nitrosylation of MYCN—a post-translational modification that would normally restrain the oncogene—thereby allowing ER stress to run unchecked.

Using RNA-seq data from 500 TCGA-PRAD patients and 4,983 Decipher GRID patients, the team confirmed that ER stress markers (IRE1, CANX, CHOP, XBP1, PDI, BiP) are significantly upregulated in high-grade tumors (Gleason ≥ 8) and independently predict poor overall survival. NOS3 expression was positively correlated with multiple ER stress genes, suggesting that NO pathway dysregulation is mechanistically coupled to the stress response rather than coincidental. In cell models spanning androgen-sensitive LNCaP, castration-resistant 22Rv1, and NEPC H660 lines—plus murine MyC-CaP cells engineered to progressively lose androgen receptor expression—the authors documented increasing mitochondrial dysfunction, reactive oxygen species accumulation, and UPR activation as cells became more neuroendocrine in character.

Critically, exogenous NO supplementation restored S-nitrosylation of MYCN at three cysteine residues (Cys4, Cys186, Cys464), reducing its oncogenic activity. This was accompanied by measurable decreases in canonical UPR branches (IRE1α, PERK, ATF6), suppressed NEPC cell proliferation, and impaired colony formation in vitro. In an orthotopic murine NEPC xenograft model, NO-treated animals showed substantially reduced primary tumor burden and markedly less metastasis to liver and brain compared with controls. Neuroendocrine differentiation markers chromogranin A and synaptophysin were correspondingly diminished. NO treatment also attenuated calcium-mediated mitochondrial dysfunction and shifted metabolic profiles away from stress-adapted glycolysis.

The implications are significant for both cancer biology and therapeutic development. The study provides the first direct mechanistic link between MYCN-driven ER stress and impaired NO/S-nitrosylation homeostasis in NEPC. Because NO donors and eNOS-activating agents are already clinically available, the findings open a relatively accessible translational path. However, the work remains preclinical, and the precise dosing, delivery mechanism, and systemic tolerability of NO-based regimens in prostate cancer patients remain to be established.